Pfizer Inc. and Sanofi-Aventis will have to wait a little longer to launch inhaled insulin (Exubera). FDA is taking a three month extension on the review, meaning a decision should come before the end of January.
Pfizer says the delay is to allow time for FDA "to review additional technical chemistry data submitted by the companies."...